STELLA PHARMA CORPORATION (4888) AI Stock Analysis

• Market Cap: ¥14.09B
• Dividend Yield: N/A
• Average Volume (3M): 332.29K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.91
• Revenue Growth: 248.15%
• EPS Growth: 76.92%
• Country: JP
• Employees: 44
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -6.00
• Shares Outstanding: 34,034,100
• 10 Day Avg. Volume: 566,500
• 30 Day Avg. Volume: 332,290
• PEG Ratio: 1.10
• Price to Book (P/B): 3.99
• Price to Sales (P/S): 13.30
• P/FCF Ratio: 93.66
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 60 Neutral
• Price Target: ¥481.00 ▲(136.95% Upside)
• Action: Reiterated Date: 02/28/26
• Date: Action: Reiterated 02/28/26

The score is driven primarily by improving financial fundamentals (rapid revenue growth, strong equity base, and positive free cash flow) and strong technical uptrend signals. These positives are meaningfully offset by continued losses (negative P/E) and overextended momentum indicators that increase near-term risk.

Positive Factors

Rapid revenue growth

Sustained, large revenue gains indicate successful product adoption and expanding market penetration. This durable top-line momentum supports future scale benefits, R&D reinvestment, and the potential to reach operating leverage if margins are addressed and growth continues over the next 2–6 months.

Strong equity position / low leverage

A solid equity base and low debt provide financial flexibility to fund clinical programs, absorb setbacks, and invest in commercialization without immediate refinancing. This structural strength reduces solvency risk and supports longer-term strategic options for a biotech firm.

Positive free cash flow and operating cash flow

The shift to positive operating and free cash flow signals improving cash generation capability, enabling coverage of near-term operating needs and reducing reliance on external funding. This durable improvement enhances sustainability of operations and strategic execution.

Negative Factors

Ongoing net losses and negative margins

Persistent net losses and negative margins constrain the company's ability to convert revenue growth into profitability. If losses continue, long-term viability depends on improving operating efficiency or sizable margin gains; otherwise cash burn could re-emerge despite recent FCFs.

Weak cash conversion vs. reported earnings

Low operating cash flow relative to net income indicates limited earnings quality and potential reliance on non-cash items or one-time improvements. This reduces predictability of sustainable cash generation and increases financing risk if profitability metrics do not improve.

Potential equity erosion from continued losses

Although equity is currently strong, sustained losses can erode shareholder equity over time, weakening the balance sheet and reducing financial flexibility. This structural risk could limit ability to fund trials or commercialization without dilutive financing or debt.

STELLA PHARMA CORPORATION Business Overview & Revenue Model

Company Description

Stella Pharma Corporation engages in the research, development, manufacturing, and distribution of pharmaceuticals. The company develops drugs for boron neutron capture therapy (BNCT). Its product includes SPM-011, a boron-containing drug for BNCT used for treating head and neck cancer, recurrent malignant glioma and meningioma, and malignant melanoma and angiosarcoma. The company was incorporated in 2007 and is headquartered in Osaka, Japan.

How the Company Makes Money

STELLA PHARMA CORPORATION generates revenue primarily through the commercialization of its pharmaceutical products, which includes both direct sales to healthcare providers and partnerships with larger pharmaceutical companies for distribution and marketing. The company also engages in research collaborations and licensing agreements that allow it to receive upfront payments, milestone payments, and royalties based on the sales of partnered products. Additionally, government grants and funding for research projects contribute to its earnings. The firm’s strategic partnerships with renowned research institutions and healthcare organizations further enhance its revenue potential by expanding its market reach and accelerating the development of new therapies.

STELLA PHARMA CORPORATION Financial Statement Overview

Summary

Strong revenue growth and a solid equity position support the score, and cash flow improved to positive free cash flow in 2025. However, ongoing net losses and negative margins remain a major weakness and cap the financial performance rating.

Income Statement

The company has shown significant revenue growth over the years, with a remarkable increase from ¥100 million in 2022 to ¥961 million in 2025. However, the company is not profitable yet, as it continues to report negative net income and EBIT. Profit margins are negative, which is a concern as it indicates ongoing operational challenges.

Balance Sheet

The balance sheet shows a strong equity position with Stockholders' Equity consistently higher than Total Debt, resulting in a low Debt-to-Equity ratio. The equity ratio is robust, reflecting a stable financial structure. However, the presence of high net losses could affect future equity levels if not addressed.

Cash Flow

The company has improved its cash flow position, transitioning from negative free cash flow in earlier years to positive free cash flow in 2025. Operating cash flow has also turned positive, which is a positive sign for operational efficiency. However, the ratio of operating cash flow to net income is low due to significant net losses.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	991.86M	961.06M	269.49M	229.07M	100.10M	205.97M
Gross Profit	871.90M	828.72M	203.69M	192.36M	50.73M	165.24M
EBITDA	-43.84M	-55.52M	-725.26M	-771.73M	-707.77M	-649.12M
Net Income	-135.73M	-140.81M	-763.75M	-778.82M	-767.72M	-659.24M
Balance Sheet
Total Assets	5.06B	5.42B	3.82B	4.33B	4.72B	2.05B
Cash, Cash Equivalents and Short-Term Investments	2.85B	3.21B	2.35B	2.71B	3.28B	1.25B
Total Debt	727.12M	766.78M	933.30M	1.09B	1.25B	1.41B
Total Liabilities	2.01B	2.21B	1.44B	1.58B	1.64B	1.82B
Stockholders Equity	3.05B	3.21B	2.38B	2.75B	3.08B	230.72M
Cash Flow
Free Cash Flow	0.00	136.50M	-887.82M	-853.07M	-1.13B	-793.58M
Operating Cash Flow	0.00	140.41M	-876.84M	-827.67M	-1.08B	-772.81M
Investing Cash Flow	0.00	287.58M	-9.01M	-29.93M	-350.56M	-22.86M
Financing Cash Flow	0.00	725.78M	228.25M	291.69M	3.46B	39.92M

STELLA PHARMA CORPORATION Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 203.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4888, the sentiment is Neutral. The current price of 203 is below the 20-day moving average (MA) of 439.95, below the 50-day MA of 349.08, and below the 200-day MA of 346.51, indicating a neutral trend. The MACD of 29.76 indicates Positive momentum. The RSI at 49.78 is Neutral, neither overbought nor oversold. The STOCH value of 33.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4888.

STELLA PHARMA CORPORATION Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4888	60 Neutral	¥14.09B	-8.45	―	―	248.15%	76.92%
7774	54 Neutral	¥25.99B	-34.16	―	―	-5.65%	-469.19%
4571	52 Neutral	¥12.74B	-12.44	-26.70%	―	172.39%	8.27%
4974	52 Neutral	¥138.00B	-8.84	―	2.18%	-0.16%	-802.20%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4593	50 Neutral	¥54.41B	-13.30	―	―	-82.33%	47.73%
4599	43 Neutral	¥19.12B	-11.30	―	―	―	11.34%